Feasibility of asymmetric flow field-flow fractionation coupled to ICP-MS for the characterization of wear metal particles and metalloproteins in biofluids from hip replacement patients.
about
Single Particle ICP-MS: Advances toward routine analysis of nanomaterials.Field flow fractionation techniques to explore the "nano-world".Silver nanoparticles as a medical device in healthcare settings: a five-step approach for candidate screening of coating agents.Detection of lead nanoparticles in game meat by single particle ICP-MS following use of lead-containing bullets.Detection and characterisation of aluminium-containing nanoparticles in Chinese noodles by single particle ICP-MS.Mechanistic insights into transferable polymyxin resistance among gut bacteria.Interaction of silver nanoparticles with metallothionein and ceruloplasmin: impact on metal substitution by Ag(i), corona formation and enzymatic activity.An Evolutionarily Conserved Mechanism for Intrinsic and Transferable Polymyxin Resistance.Defining ICR-Mo, an intrinsic colistin resistance determinant from Moraxella osloensis.Validating a Single-Particle ICP-MS Method to Measure Nanoparticles in Human Whole Blood for Nanotoxicology
P2860
Q38873865-2CF2C1F1-D4F0-4FB5-A548-38817F30729EQ39100093-58859AF3-1B08-4453-B2C8-4132D8D507F5Q48094580-B461C919-992A-4557-9AD1-5D43B2D9BB55Q48158219-702BDB01-CA5C-4624-AA54-BD4F221F7242Q48315294-72211484-0965-48D1-BE38-6DB848D5986DQ49806518-9BF86E8A-D08C-4884-82C2-5307F780EF22Q51018969-EE6EB5F5-1A3F-4895-B2F2-FC2E6DE66926Q52595439-18FF150F-653F-4B24-8AE5-51A7F4049CB4Q55224837-2E68ACC2-0053-45FB-9287-DB6D7A362CFCQ58279688-324BFDB9-B698-4C5B-8084-6AB8D6FE90B4
P2860
Feasibility of asymmetric flow field-flow fractionation coupled to ICP-MS for the characterization of wear metal particles and metalloproteins in biofluids from hip replacement patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Feasibility of asymmetric flow ...... from hip replacement patients.
@en
Feasibility of asymmetric flow ...... from hip replacement patients.
@nl
type
label
Feasibility of asymmetric flow ...... from hip replacement patients.
@en
Feasibility of asymmetric flow ...... from hip replacement patients.
@nl
prefLabel
Feasibility of asymmetric flow ...... from hip replacement patients.
@en
Feasibility of asymmetric flow ...... from hip replacement patients.
@nl
P2093
P2860
P1476
Feasibility of asymmetric flow ...... from hip replacement patients.
@en
P2093
David J Langton
Erik H Larsen
Jacque-Lucca Kearney
Katrin Loeschner
P2860
P2888
P304
P356
10.1007/S00216-015-8631-4
P407
P577
2015-04-15T00:00:00Z